All In Biotech

Drug Trial Radar · NCT06220201

A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

A Phase 1, Multicenter, Single-arm, Dose-escalation Study of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants With Autoimmune Neurological Diseases: Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS), or Refractory Myasthenia Gravis (MG).

Last checked: Nov 20, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Mar 28, 2024

Primary completion

Jul 15, 2027

Study completion Jul 15, 2027

Sponsor

Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
Sponsor type
Industry
Collaborators
Celgene Corporation
First posted
Jan 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, efficacy, and drug levels of CC-97540 in participants with Relapsing Forms of Multiple Sclerosis (RMS), Progressive Forms of Multiple Sclerosis (PMS) or Refractory Myasthenia Gravis (MG).

Conditions

  • Multiple Sclerosis
  • Myasthenia Gravis

Interventions

  • CC-97540Drug

    Specified dose on specified days

  • FludarabineDrug

    Specified dose on specified days

  • CyclophosphamideDrug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events (AEs)Time frame: Up to week 104
  2. Number of participants with serious adverse events (SAEs)Time frame: Up to week 104
  3. Number of participants with adverse events of special interest (AESIs)Time frame: Up to week 104
  4. Number of participants with laboratory test result abnormalitiesTime frame: Up to week 104
  5. Number of participants with imaging abnormalitiesTime frame: Up to week 104
  6. Number of participants with dose-limiting toxicities (DLTs)Time frame: Up to week 104
  7. Recommended Phase 2 dose (RP2D) based on the incidence of DLTs that occur during the DLT evaluation periodTime frame: Up to week 104

Locations

34 sites in 6 countries. Site status is shown where the registry gives one.

  • Local Institution - 0011

    Birmingham, Alabama

  • University of California, Irvine

    Irvine, California

  • University of Colorado Anschutz Medical Campus

    Aurora, Colorado

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Yale-New Haven Hospital

    North Haven, Connecticut

  • University of Kansas Medical Center

    Kansas City, Kansas

  • Local Institution - 0005

    Boston, Massachusetts

  • Washington University School of Medicine

    St Louis, Missouri

  • Hackensack University Medical Center

    Hackensack, New Jersey

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Neurological Institute of New York

    New York, New York

  • University of Cincinnati Medical Center

    Cincinnati, Ohio

  • Cleveland Clinic Mellen Center

    Cleveland, Ohio

  • Oregon Health and Science University

    Portland, Oregon

  • Swedish Medical Center

    Seattle, Washington

  • Medical College of Wisconsin

    Milwaukee, Wisconsin

  • Antwerp University Hospital

    Edegem, Antwerpen, Belgium

  • UZ Gent

    Ghent, Oost-Vlaanderen, Belgium

  • Hopital Claude Huriez - CHU de Lille

    Lille, Nord, France

  • Pitie Salpetriere University Hospital

    Paris, Ville de Paris, France

  • Local Institution - 0033

    Düsseldorf, Germany

  • Universitaetsklinikum Erlangen

    Erlangen, Germany

  • Klinikum der Universität München Großhadern

    München, Germany

  • Universitaetsklinikum Essen

    Essen, North Rhine-Westphalia, Germany

  • Universitaetsklinikum Magdeburg

    Magdeburg, Saxony-Anhalt, Germany

  • Hospital Universitari i Politecnic La Fe

    Valencia, Spain

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona [Barcelona], Spain

  • Local Institution - 0016

    Barcelona, Barcelona [Barcelona], Spain

  • Hospital Clínic de Barcelona

    Barcelona, Catalunya [Cataluña], Spain

  • Hospital Universitario Ramón y Cajal

    Madrid, Madrid, Comunidad de, Spain

  • Barts Health NHS Trust

    London, United Kingdom

  • Manchester Royal Infirmary

    Manchester, Lancashire, United Kingdom

  • University College London Hospital

    London, London, City of, United Kingdom

  • Salford Royal Hospital

    Salford, Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.